- Stocks
- Pharma & Healthcare
- Hamps Bio
Hamps Bio share price
NSE: HAMPSPharma & HealthcarePharmaceutical Retailers
Hamps Bio at a glance
With a market capitalisation of ₹22 Cr, it ranks 3540th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Pharmaceutical Retailers.
Its return on equity was 3.4% in FY25. Promoters held 71.99% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹22 CrRank 3540 on NSE
- Price to book
- 2.12×FY25
- ROE
- 3.4%FY25
- ROCE
- 5.0%FY25
- Debt to equity
- 0.34FY25
- Net profit margin
- 4.5%FY25
- Book value / share
- ₹20.20FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Hamps Bio financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹5 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr |
| Operating profit | −₹0 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| Net profit | −₹0 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| EPS (₹) | −₹1.43 | −₹1.49 | ₹0.51 | ₹1.50 | ₹1.76 | ₹0.68 |
| Cash from operations | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | −₹0 Cr | −₹2 Cr |
| Total debt | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr |
| Shareholders' equity | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹9 Cr |
Hamps Bio shareholding pattern
| Holder | 18 Dec 2024 | 31 Mar 2025 | 17 Sep 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|
| Promoters | 71.99% | 71.99% | 71.99% | 71.99% | 71.99% |
| Non-institutions | 27.78% | 28.01% | 28.01% | 28.01% | 28.01% |
Hamps Bio vs peers
The listed Pharma & Healthcare companies nearest to Hamps Bio by market capitalisation.
Ask anything about Hamps Bio
Pivot answers on the live chart with evidence you can check, and tests strategies against HAMPS's own history. Try: “Why has HAMPS moved over the last three months?” · “Backtest a 50-day moving-average crossover on HAMPS over five years” · “Compare HAMPS with SUPHA on margins and valuation”
Frequently asked questions about Hamps Bio
What is the market cap of Hamps Bio?
Hamps Bio's market capitalisation is ₹22 Cr (₹22 Cr) at the 22 Oct 2026 close, ranking 3540th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Hamps Bio?
Return on equity was 3.4% in FY25 and return on capital employed was 5.0% in FY25 (standalone figures).
Is Hamps Bio a debt-free company?
No. Hamps Bio's debt-to-equity ratio was 0.34 in FY25, with total debt of ₹2 Cr.
What is the shareholding pattern of Hamps Bio?
As of 31 Mar 2026: promoters 71.99%, non-institutions 28.01%.
Who are Hamps Bio's competitors?
The listed Pharma & Healthcare companies closest to Hamps Bio by market cap are SUPHA PHARMACHE, Transgene Biote, Rekvina Labs, Adeshwar Medite, Maitri and Desh Rakshak.
Is Hamps Bio a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Hamps Bio's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HAMPS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with H · all NSE stocks · this page as text